FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.
Commentary|Articles|September 28, 2026
Compounding at a Crossroads: Why Safety Standards Are the Industry's Best Defense
Author(s)Matthew Montes de Oca
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
Advertisement
Advertisement
Compounding pharmacy is having a moment, and not all of it is good.
Related to this article
FDA approves Onswik, Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes.
Six years after Rutledge, new court rulings, federal PBM reforms, and state ownership bans are redrawing the limits of pharmacy benefit regulation.
Chairs of Europe's largest drugmakers urge the EU to boost health spending, speed up clinical trials, and strengthen IP protections before falling further behind the US and China.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
FDA has approved Bayer's Kerendia to reduce disease progression risk in adults with chronic kidney disease associated with type 1 diabetes.
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.
Advertisement
Advertisement